Malaria
Conditions
Interventions
PDMC drugs collected from the nearest health facility or village clinic
All PDMC treatment courses given at discharge.
Sponsors
Training and Research Unit of Excellence
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Severe malaria or haemoglobin 5kgs 4. Clinically stable, able to switch to oral medication 5. Subject completed blood transfusion in accordance with routine hospital practice 6. Absence of known cardiac problems 7. Provision of informed consent by parent or guardian
Exclusion criteria
Exclusion criteria: 1. Recognised specific other causes of severe anaemia (e.g., trauma, haematological malignancy, known bleeding disorder) 2. Known sickle cell 3. Known hypersensitivity to the study drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 100% of PDMCC drug uptake (defined as administration of all 3-day treatment courses, given 4, 8 and 12 weeks after discharge) assessed by unannounced spot checks. | — |
Secondary
| Measure | Time frame |
|---|---|
| 60% of PDMCC drugs (defined as administration of 6 or more [but less than 9] of the daily dosages out of the total of 9, given 2, 6 and 10 weeks after discharge;30% of PDMCC drugs (defined as administration of 3 or more [but less than 6] of the daily dosages out of the total of 9, given 2, 6 and 10 weeks after discharge;<30% of PDMCC drugs (defined as administration of less than 3 of the daily dosages out of the total of 9, given 2, 6 and 10 weeks after discharge;Proportion of all the children eligible to be provided with PDMC that were actually prescribed PDMC drugs.;Proportion of all children eligible to be provided with all their PDMCC drugs at discharge that were actually provided with at least one of their PDMCC treatment course.;Proportion of all children eligible to be provided with their PDMC drugs through monthly visits that were actually provided with at least one of their PDMC treatment course.;Proportion of all children eligible to be provided with their PDMC drugs through monthly visits that were actually provided with a) PDMC 1; b) PDMC 2; and c) PDMC 3 treatment courses.;Cost of delivering the PDMC services (providers perspective);Cost of receiving the PDMC services (patients’ perspective);The acceptability of PDMC. This will be assessed through qualitative surveys. ;Adaptations to their working practices required to implement PDMC.;Perceptions of the feasibility of implementing PDMCC through different delivery mechanisms;All-cause mortality;Incidence rate of all-cause hospital readmission;Incidence rate of readmissions due to severe anaemia (Hb <5g/dL) or severe malaria ;Incidence rate of non-severe all-cause sick-child clinic visits;Incidence rate of clinic visits due to RDT/microscopy confirmed non-severe malaria;Policy adoption outcome- Chronological timeline of events ;Contextual factors leading to decisions ;Criteria/considerations for decision making ;Barriers encountered in the process;Facilitators encountered in the process;Adherence to other | — |
Countries
Malawi
Contacts
Public ContactTinashe Tizifa
Postdoctoral Researcher
Outcome results
None listed